Metz Tumor Progress Express (Issue 009)

：，
。
。enjoy～

：，
。
。enjoy～：，
。
。enjoy～

：（008）

（008）（008）（008）

1.

Ann Oncol：（pembrolizumab）+：KEYNOTE-189

1.
Ann Oncol：（pembrolizumab）+：KEYNOTE-1891.
Ann Oncol：（pembrolizumab）+：KEYNOTE-1891.
Ann Oncol：（pembrolizumab）+：KEYNOTE-1891.
Ann Oncol：（pembrolizumab）+：KEYNOTE-189

KEYNOTE-189 (NCT02578680) is a double-blind, randomized, placebo-controlled phase III clinical study conducted in 126 cancer centers in 16 countries
.

To evaluate the efficacy and safety of pembrolizumab combined with pemetrexed + platinum in the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer compared with placebo combined with pemetrexed + platinum

KEYNOTE-189 (NCT02578680) is a double-blind, randomized, placebo-controlled phase III clinical study conducted in 126 cancer centers in 16 countries

Preliminary analysis confirmed that pembrolizumab (pembrolizumab) can improve patients' PFS and OS

The study believes that pembrolizumab combined with pemetrexed + platinum first-line treatment can improve the prognosis of metastatic non-squamous non-small cell lung cancer, and the toxicity is controllable and tolerable

For details refer to: Ann Oncol: Pembrolizumab combined with pemetrexed + platinum for the efficacy and safety of patients with metastatic non-squamous non-small cell lung cancer: KEYNOTE-189 For details refer to: Ann Oncol: Pembrol Efficacy and safety of pembrolizumab combined with pemetrexed + platinum in the treatment of patients with metastatic non-squamous non-small cell lung cancer: KEYNOTE-189 Fordetails, please refer to:Ann Oncol: Pembrolizumab combined with pembrolizumab Efficacy and safety of metrexide+platinum in the treatment of patients with metastatic non-squamous non-small cell lung cancer: KEYNOTE-189Reference for details:Ann Oncol: Pembrolizumab combined with pembrolizumab+platinum in the treatment of metastases Efficacy and safety of patients with advanced non-squamous non-small cell lung cancer: KEYNOTE-189Details reference:Details reference:Details reference:Details reference:Ann Oncol: Pembrolizumab (pembrolizumab) combined with pemetrexed + platinum therapy Efficacy and safety of patients with metastatic non-squamous non-small cell lung cancer: KEYNOTE-189Ann Oncol: Pembrolizumab (pembrolizumab) combined with pemetrexed + platinum in the treatment of patients with metastatic non-squamous non-small cell lung cancer Efficacy and safety: KEYNOTE-189

2.

J Immunother Cancer: The efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma

2.

A US research team conducted a phase II study to evaluate the efficacy and safety of IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma

The study is a single-arm phase II study, and immune checkpoint inhibitors include pembrolizumab (P), nivolumab (N), or ipilimumab (I)

Studies have shown that IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) has curative effect and controllable toxicity in the treatment of advanced melanoma, and it is worthy of further exploration in the future

For details refer to: J Immunother Cancer: IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) in the treatment of advanced melanoma efficacy and safety For details refer to: J Immunother Cancer: IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab Fordetailsof the efficacy and safety of pembrolizumab in the treatment of advanced melanoma,please refer to:J Immunother Cancer: IDO inhibitor indoximod combined with PD1 inhibitor pembrolizumab (pembrolizumab) for the efficacy and safety of advanced melanoma.

3.

Percutaneous cryoablation (PCA) is the treatment option for more and more patients with stage I renal cell carcinoma (RCC)

Recently, a study published in the Journal of Radiology prospectively evaluated the 10-year tumor prognosis of patients with stage I RCC treated with PCA, and compared receiving partial nephrectomy by using a matched cohort from the National Cancer Database (NCDB) ( The prognosis of patients with PN) and radical nephrectomy (RN), as well as the influence of PCA on long-term renal function and the risk of metachronous diseases, provide a reliable reference for the formulation of clinical personalized treatment plans

Data from a 10-year prospective observational study of patients with stage I renal cell carcinoma (RCC) in this study showed that percutaneous cryoablation (PCA) provides a good disease-specific survival equivalent to surgical treatment

For details, please refer to: Radiology: For the treatment of stage 1 renal cell carcinoma, don't just know everything! Reference for details:Reference fordetails:Reference fordetails:Referencefor details: Reference fordetails:Reference fordetails:Reference fordetails:Radiology: For the treatment of stage 1 renal cell carcinoma, don't just know everything!

4.
Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors

4.
Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors 4.
Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors 4.
Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors

A research team from Taiwan, China, used meta-analysis to summarize the efficacy and safety of S-1 chemotherapy combined with radiotherapy in the treatment of head and neck tumors
.
Related research results are published on Cancers
.

A research team from Taiwan, China, used meta-analysis to summarize the efficacy and safety of S-1 chemotherapy combined with radiotherapy in the treatment of head and neck tumors
.
Related research results are published on Cancers
.
A research team from Taiwan, China, used meta-analysis to summarize the efficacy and safety of S-1 chemotherapy combined with radiotherapy in the treatment of head and neck tumors
.
Related research results are published on Cancers
.
A research team from Taiwan, China, used meta-analysis to summarize the efficacy and safety of S-1 chemotherapy combined with radiotherapy in the treatment of head and neck tumors
.
Related research results are published on Cancers
.

Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
.
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC
.
The study included 3 randomized clinical studies and 9 single-arm clinical studies with a total of 378 patients
.

Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
.
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC
.
The study included 3 randomized clinical studies and 9 single-arm clinical studies with a total of 378 patients
.
Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
.
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC
.
The study included 3 randomized clinical studies and 9 single-arm clinical studies with a total of 378 patients
.
Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
.
The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC
.
The study included 3 randomized clinical studies and 9 single-arm clinical studies with a total of 378 patients
.
The study included 3 randomized clinical studies and 9 single-arm clinical studies with a total of 378 patients
.

The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.

The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.
The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.
The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.
The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.
The meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
.
Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two
.

For details, please refer to: Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors

Details Reference: Cancers: Meta - Analysis of S-1 radiotherapy of head and neck cancer treatment efficacy and safety details reference: Cancers: Meta - Analysis of S-1 radiotherapy of head and neck cancer treatment efficacy and safety details reference :Cancers: Meta-analysis of the efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors.
Fordetails, please refer to: Fordetails: Fordetails, please refer to: Fordetails:Cancers: For the efficacy and efficacy of radiotherapy combined with S-1 in the treatment of head and neck tumors.
safety Meta-analysisCancers: Meta analysis of S-1 radiotherapy efficacy and safety of treatment of head and neck tumorsCancers: S-1 radiotherapy Meta-analysis of the efficacy and safety of the treatment of head and neck cancerCancers: radiotherapy Meta-analysis of the efficacy and safety of combined S-1 in the treatment of head and neck tumors

5.
Cancers: the clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: a prospective COLOSPOT study

5.
Cancers: the clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: prospective COLOSPOT study 5.
Cancers: the clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: prospective COLOSPOT study 5.
Cancers: The clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: a prospective COLOSPOT study

The research team from France constructed the CK19-EPISPOT assay and carried out a prospective study COLOSPOT, mainly using the CK19-EPISPOT assay and CellSearch ®system to detect CTCs, and to evaluate the use of FOLFIRI-bevacizumab in the treatment of CTCs.
The prognostic value of patients with metastatic colorectal cancer
.
Related research results were published in the journal Cancers
.

The research team from France constructed the CK19-EPISPOT assay and carried out a prospective study COLOSPOT, mainly using the CK19-EPISPOT assay and CellSearch ®system to detect CTCs, and to evaluate the use of FOLFIRI-bevacizumab in the treatment of CTCs.
The prognostic value of patients with metastatic colorectal cancer
.
Related research results were published in the journal Cancers
.
The research team from France constructed the CK19-EPISPOT assay and carried out a prospective study COLOSPOT, mainly using the CK19-EPISPOT assay and CellSearch ®system to detect CTCs, and to evaluate the use of FOLFIRI-bevacizumab in the treatment of CTCs.
The prognostic value of patients with metastatic colorectal cancer
.
Related research results were published in the journal Cancers
.
The research team from France constructed the CK19-EPISPOT assay and carried out a prospective study COLOSPOT, mainly using the CK19-EPISPOT assay and CellSearch ®system to detect CTCs, and to evaluate the use of FOLFIRI-bevacizumab in the treatment of CTCs.
The prognostic value of patients with metastatic colorectal cancer
.
Related research results were published in the journal Cancers
.

The study was carried out in 11 research centers in France, and patients were treated with FIOLFIRI-bevacizumab
.
The EPISPOT assay was used to detect CTCs at baseline (D 0 ), day 14 (D 14 ), day 28 (D 28 ), day 42 (D 42) and day 56 (D 56 ); while CellSearch ® system was used CTCs were detected at the patient's baseline (D 0 ), and on the 28th day (D 28 )
.
Evaluate the relationship between CTCs and PFS and OS at different time points
.
The study included 155 evaluable patients with a median follow-up of 24.
5 months (range, 0.
99–75.
04 months), median PFS and OS were 9.
4 months (95% CI, 8.
1–10.
2 months) and 26.
2 months ( 95% CI, 21.
3–29.
8 months)
.

The study was carried out in 11 research centers in France, and patients were treated with FIOLFIRI-bevacizumab
.
The EPISPOT assay was used to detect CTCs at baseline (D 0 ), day 14 (D 14 ), day 28 (D 28 ), day 42 (D 42) and day 56 (D 56 ); while CellSearch ® system was used CTCs were detected at the patient's baseline (D 0 ), and on the 28th day (D 28 )
.
Evaluate the relationship between CTCs and PFS and OS at different time points
.
The study included 155 evaluable patients with a median follow-up of 24.
5 months (range, 0.
99–75.
04 months), median PFS and OS were 9.
4 months (95% CI, 8.
1–10.
2 months) and 26.
2 months ( 95% CI, 21.
3–29.
8 months)
.

Univariate analysis showed that early CTC dynamics (two detection methods), ECOG PS at D0, and BRAF mutation status were predictors of PFS and OS
.
The primary tumor of the right colon was also significantly associated with poor OS
.
In multivariate analysis, according to CK19-EPISPOT to detect the dynamic changes of D0-D28 CTC (HR 2.
445, 95% CI (1.
04-5.
78), p = 0.
0414) and CellSearch® system to detect the dynamic changes of D0-D28 CTC (HR 2.
461, 95 % CI (1.
06-5.
74), p = 0.
037) is still a significant predictor of PFS, but not a significant predictor of OS
.

Univariate analysis showed that early CTC dynamics (two detection methods), ECOG PS at D0, and BRAF mutation status were predictors of PFS and OS
.
The primary tumor of the right colon was also significantly associated with poor OS
.
In multivariate analysis, according to CK19-EPISPOT to detect the dynamic changes of D0-D28 CTC (HR 2.
445, 95% CI (1.
04-5.
78), p = 0.
0414) and CellSearch® system to detect the dynamic changes of D0-D28 CTC (HR 2.
461, 95 % CI (1.
06-5.
74), p = 0.
037) is still a significant predictor of PFS, but not a significant predictor of OS
.

Studies have shown that the detection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.

Studies have shown that the detection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.
Studies have shown that the detection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.
Studies have shown that the detection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.
Studies have shown that thedetection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.
Studies have shown that thedetection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.
The detection of D28 and D0-D28 circulating tumor cells (CTCs) is related to the prognosis of patients with colorectal cancer and can be used to monitor the efficacy of FOLFIRI-bevacizumab therapy
.

For details, please refer to: Cancers: The clinical correlation between circulating tumor cells (CTCs) and patients with metastatic colorectal cancer: a prospective COLOSPOT study

Reference for details: Reference fordetails:Reference fordetails:Reference for details: Reference for details:Reference fordetails:Reference fordetails:Cancers: Clinical relevance of circulating tumor cells (CTCs) to patients with metastatic colorectal cancer: Prospective COLOSPOT study

6.
JGH: The independent predictor of high-grade superficial non-ampullary duodenal epithelial tumors is tumor location and size

6.
JGH: The independent predictor of high-grade superficial non-ampullary duodenal epithelial tumors is tumor location and size 6.
JGH: The independent predictor of high-grade superficial non-ampullary duodenal epithelial tumors is tumor location And size 6.
JGH: independent predictors of high-grade superficial non-ampullary duodenal epithelial tumors are tumor location and size

With the continuous advancement of endoscopy technology and diagnosis , researchers have realized that the incidence of superficial non-ampullary duodenal epithelial tumors (SNADET) has been increasing
.
However, the clinical features of SNADET with malignant potential remain unclear
.
Therefore, the purpose of this study is to clarify the clinical characteristics of high-level SNADEN
.

With the continuous advancement of endoscopy technology and diagnosis , researchers have realized that the incidence of superficial non-ampullary duodenal epithelial tumors (SNADET) has been increasing
.
However, the clinical features of SNADET with malignant potential remain unclear
.
Therefore, the purpose of this study is to clarify the clinical characteristics of high-level SNADEN
.
With the continuous advancement of endoscopy technology and diagnosis , researchers have realized that the incidence of superficial non-ampullary duodenal epithelial tumors (SNADET) has been increasing
.
Withthe continuous advancementof endoscopy technology and diagnosis , researchers have realized that the incidence of superficial non-ampullary duodenal epithelial tumors (SNADET) has been increasing
.
Withthe continuous advancementof endoscopy technology anddiagnosis, researchers have realized that the incidence of superficial non-ampullary duodenal epithelial tumors (SNADET) has been increasing
.
DiagnosisHowever, the clinical features of SNADET with malignant potential remain unclear
.
Therefore, the purpose of this study is to clarify the clinical characteristics of high-level SNADEN
.
However, the clinical features of SNADET with malignant potential remain unclear
.
Therefore, the purpose of this study is to clarify the clinical characteristics of high-level SNADEN
.

The researchers identified 328 SNALET cases that were resected endoscopically or surgically from January 2013 to April 2019 from the endoscopy and pathology database
.
Then the clinical features of these patients' low-grade mucosal tumors (n = 154) and high-grade mucosal tumors/submucosal carcinoma (HGN/SMC, n = 174) were compared
.

The researchers identified 328 SNALET cases that were resected endoscopically or surgically from January 2013 to April 2019 from the endoscopy and pathology database
.
Then the clinical features of these patients' low-grade mucosal tumors (n = 154) and high-grade mucosal tumors/submucosal carcinoma (HGN/SMC, n = 174) were compared
.
The researchers identified 328 SNALET cases that were resected endoscopically or surgically from January 2013 to April 2019 from the endoscopy and pathology database
.
Then the clinical features of these patients' low-grade mucosal tumors (n = 154) and high-grade mucosal tumors/submucosal carcinoma (HGN/SMC, n = 174) were compared
.
The researchers identified 328 SNALET cases that were resected endoscopically or surgically from January 2013 to April 2019 from the endoscopy and pathology database
.
Then the clinical features of these patients' low-grade mucosal tumors (n = 154) and high-grade mucosal tumors/submucosal carcinoma (HGN/SMC, n = 174) were compared
.

This study confirmed that the anterior ampullary position and the size of the large tumor are independent predictors of HGN/SMC type SNAET
.
The location of the preampullary tumor is significantly related to the gastric histological phenotype
.

This study confirmed that the anterior ampullary position and the size of the large tumor are independent predictors of HGN/SMC type SNAET
.
The location of the preampullary tumor is significantly related to the gastric histological phenotype
.

For details, refer to: JGH: Independent predictors of high-grade superficial non-ampullary duodenal epithelial tumors are tumor location and size

Reference for details: Reference fordetails:Reference fordetails:Reference for details: Reference for details:Reference fordetails:Reference fordetails:JGH: Independent predictors of high-grade superficial non-ampullary duodenal epithelial tumors are tumor location and size

7.
JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma

7.
JCO: FOXR2 can stabilize MYCN protein, which can be used as an independent predictor of adverse outcomes in patients with neuroblastoma.
7.
JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma.
7.
JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma

The clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to death
.
Therefore, understanding the mechanisms that lead to tumor progression is essential for the treatment of patients
.
In this study, the researchers found that FOXR2 activation can identify a subtype of neuroblastoma with unfavorable outcomes, and investigated the molecular mechanism of FOXR2 associated with adverse patient outcomes
.

The clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to death
.
Therefore, understanding the mechanisms that lead to tumor progression is essential for the treatment of patients
.
In this study, the researchers found that FOXR2 activation can identify a subtype of neuroblastoma with unfavorable outcomes, and investigated the molecular mechanism of FOXR2 associated with adverse patient outcomes
.
The clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to death
.
Therefore, understanding the mechanisms that lead to tumor progression is essential for the treatment of patients
.
In this study, the researchers found that FOXR2 activation can identify a subtype of neuroblastoma with unfavorable outcomes, and investigated the molecular mechanism of FOXR2 associated with adverse patient outcomes
.
The clinical outcomes of patients with neuroblastoma range from spontaneous tumor regression to death
.
Therefore, understanding the mechanisms that lead to tumor progression is essential for the treatment of patients
.
In this study, the researchers found that FOXR2 activation can identify a subtype of neuroblastoma with unfavorable outcomes, and investigated the molecular mechanism of FOXR2 associated with adverse patient outcomes
.

The researchers analyzed a total of 1,030 primary neuroblastoma cases with complete clinical annotations from three independent transcription data sets, performed immunoprecipitation on FOXR2 and MYCN , and silenced them in two neuroblastoma cell lines FOXR2 expression to examine the effect on cellular processes, transcriptome and MYCN protein levels
.
In addition, the protein levels of FOXR2 and MYCN in tumor samples were also analyzed
.

The researchers analyzed a total of 1,030 primary neuroblastoma cases with complete clinical annotations from three independent transcription data sets, performed immunoprecipitation on FOXR2 and MYCN , and silenced them in two neuroblastoma cell lines FOXR2 expression to examine the effect on cellular processes, transcriptome and MYCN protein levels
.
In addition, the protein levels of FOXR2 and MYCN in tumor samples were also analyzed
.
The researchers analyzed a total of 1,030 primary neuroblastoma cases with complete clinical annotations from three independent transcription data sets, performed immunoprecipitation on FOXR2 and MYCN , and silenced them in two neuroblastoma cell lines FOXR2 expression to examine the effect on cellular processes, transcriptome and MYCN protein levels
.
In addition, the protein levels of FOXR2 and MYCN in tumor samples were also analyzed
.
The researchers analyzed a total of 1,030 primary neuroblastoma cases with complete clinical annotations from three independent transcription data sets, performed immunoprecipitation on FOXR2 and MYCN, and silenced them in two neuroblastoma cell lines FOXR2 expression to examine the effect on cellular processes, transcriptome and MYCN protein levels
.
In addition, the protein levels of FOXR2 and MYCN in tumor samples were also analyzed
.
immunity

This study shows that FOXR2 stabilizes MYCN protein represents an alternative mechanism for MYCN amplification to increase MYCN protein levels
.
Therefore, it is sufficient to determine another group of neuroblastoma patients with unfavorable clinical outcomes based on FOXR2 expression
.

This study shows that FOXR2 stabilizes MYCN protein represents an alternative mechanism for MYCN amplification to increase MYCN protein levels
.
Therefore, it is sufficient to determine another group of neuroblastoma patients with unfavorable clinical outcomes based on FOXR2 expression
.
This study shows that FOXR2 stabilizes MYCN protein represents an alternative mechanism for MYCN amplification to increase MYCN protein levels
.
Therefore, it is sufficient to determine another group of neuroblastoma patients with unfavorable clinical outcomes based on FOXR2 expression
.
This study shows that FOXR2 stabilizes MYCN protein represents an alternative mechanism for MYCN amplification to increase MYCN protein levels
.
Therefore, it is sufficient to determine another group of neuroblastoma patients with unfavorable clinical outcomes based on FOXR2 expression
.
This study shows that FOXR2 stabilizes MYCN protein represents an alternative mechanism for MYCN amplification to increase MYCN protein levels
.
Therefore, it is sufficient to determine another group of neuroblastoma patients with unfavorable clinical outcomes based on FOXR2 expression
.

For details, refer to: JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma

For details, refer to: JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma.
For details, refer to: JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma.
Fordetails, refer to :JCO: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in neuroblastoma patients.
Fordetails: Fordetails: Fordetails: Fordetails: Fordetails:JCO: FOXR2 can stabilize MYCN protein and can be used as neuroblastomaJCO:an independent predictor of adverse outcomes in patients with tumors: FOXR2 can stabilize MYCN protein and can be used as an independent predictor of adverse outcomes in patients with neuroblastoma

8.
Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival!

8.
8.
8.
Lancet sub-news | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival! Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival! Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival!

Precision treatment provides many directions for the exploration of new drugs and new methods for malignant tumors
.
Among them, the RET gene is one of the rarer pathogenic driver genes, but it is the "source of all evil" in medullary thyroid cancer
.
RET gene mutations can be detected in about 60% of patients with medullary thyroid cancer, and the proportion of RET mutations in advanced patients is as high as 90%
.
Therefore, precise targeting of the RET gene has become the key to the treatment of medullary thyroid cancer
.

Precision treatment provides many directions for the exploration of new drugs and new methods for malignant tumors
.
Among them, the RET gene is one of the rarer pathogenic driver genes, but it is the "source of all evil" in medullary thyroid cancer
.
RET gene mutations can be detected in about 60% of patients with medullary thyroid cancer, and the proportion of RET mutations in advanced patients is as high as 90%
.
Therefore, precise targeting of the RET gene has become the key to the treatment of medullary thyroid cancer
.
Precise

Pralsetinib is an oral (once a day), highly effective and highly selective drug under development that targets RET mutations
.
The results of preclinical studies have shown that pralsetinib is sensitive to RET fusion and RET activating mutations.
Compared with VEGFR2, pralsetinib is 90 times more selective for RET, and it is also significantly improved compared with approved multi-kinase inhibitors
.

pralsetinib is sensitive to RET fusion and RET activating mutations.
Compared with VEGFR2, pralsetinib is 90-fold more selective for RET, and it is also significantly improved compared with approved multi-kinase inhibitors
.
pralsetinib is sensitive to RET fusion and RET activating mutations.
Compared with VEGFR2, pralsetinib is 90-fold more selective for RET, and it is also significantly improved compared with approved multi-kinase inhibitors
.

So what is the effect of pralsetinib, which is a specific inhibitor of RET mutations? In order to explore the above issues, experts from the University of Texas Anderson Cancer Center conducted related research, and the results were published in the latest " Lancet " sub-Journal Lancet Diabetes Endocrinology
.

Lancet

Studies have shown that Pralsetinib is a new, well-tolerated, effective, once-a-day oral treatment regimen, which is suitable for patients with RET-altered thyroid cancer
.

Studies have shown that Pralsetinib is a new, well-tolerated, effective, once-a-day oral treatment regimen, which is suitable for patients with RET-altered thyroid cancer
.
Studies have shown that Pralsetinib is a new, well-tolerated, effective, once-a-day oral treatment regimen, which is suitable for patients with RET-altered thyroid cancer
.

For details, please refer to: Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival!

Reference for details: Reference fordetails:Reference fordetails:Reference fordetails: Reference for details: Reference fordetails:Reference fordetails:Reference fordetails:Lancet sub-news | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival! Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival! Lancet Sub-Journal | RET inhibitor--Pralsetinib in the treatment of thyroid cancer, achieving a breakthrough in survival!

9.
JNCI: The best endocrine choice after adjuvant chemotherapy for perimenopausal breast cancer patients

9.
JNCI: The best endocrine choice for perimenopausal breast cancer patients after adjuvant chemotherapy 9.
JNCI: The best endocrine choice for perimenopausal breast cancer patients after adjuvant chemotherapy 9.
JNCI: The best endocrine choice for perimenopausal breast cancer patients after surgery The best endocrine choice after adjuvant chemotherapy

We know that for patients with early-stage estrogen receptor-positive (ER+) breast cancer, endocrine therapy after postoperative adjuvant chemotherapy can benefit patients
.
For premenopausal and postmenopausal patients, the efficacy of adjuvant aromatase inhibitor (AI) versus tamoxifen has been proven in randomized clinical studies
.
However, for early ER+ breast cancer patients in the perimenopausal period, the best endocrine therapy is still unclear
.

Therefore, a research team from the Netherlands carried out a study to explore the best endocrine treatment strategy after adjuvant chemotherapy for early ER+ breast cancer in perimenopause
.
Related research results were published in the Journal of the National Cancer Institute (JNCI)
.

The study showed that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after adjuvant chemotherapy after surgery is treatment containing aromatase inhibitors (AI)
.

The study showed that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after adjuvant chemotherapy after surgery is treatment containing aromatase inhibitors (AI)
.
The study showed that for patients with ER+ breast cancer aged 45-50 years, the best endocrine therapy after adjuvant chemotherapy after surgery is treatment containing aromatase inhibitors (AI)
.

For details, please refer to: JNCI: The best endocrine choice after adjuvant chemotherapy for perimenopausal breast cancer patients

Reference for details: Reference fordetails:Reference fordetails:Reference fordetails:Reference for details: Reference for details:Reference fordetails:Reference fordetails:Reference fordetails:JNCI: Best endocrine choice after adjuvant chemotherapy for patients with perimenopausal breast cancerJNCI: Perimenopausal breast The best endocrine choiceafter adjuvant chemotherapy for cancer patients JNCI: thebest endocrine choice after adjuvant chemotherapy forperimenopausal breast cancer patients JNCI: thebest endocrine choiceafter adjuvant chemotherapy forperimenopausal breast cancer patientsJNCI: perimenopausal The best endocrine choicefor breast cancer patients after adjuvant chemotherapyJNCI: Thebest endocrine choice for patients with perimenopausal breast cancer after adjuvant chemotherapyJNCI: Thebest endocrine choicefor patients with perimenopausal breast cancer after adjuvant chemotherapy

10.
Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study

10.
Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study 10.
Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases Efficacy: real-world multicenter study 10.
Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study

A research team from Hunan, China conducted a real-world study to evaluate the effect of pyrrotinib on the OS of HER2+ breast cancer patients with brain metastases
.
The research results were published in the journal Clin Cancer Res
.

A research team from Hunan, China conducted a real-world study to evaluate the effect of pyrrotinib on the OS of HER2+ breast cancer patients with brain metastases
.
The research results were published in the journal Clin Cancer Res
.
A research team from Hunan, China conducted a real-world study to evaluate the effect of pyrrotinib on the OS of HER2+ breast cancer patients with brain metastases
.
The research results were published in the journal Clin Cancer Res
.
A research team from Hunan, China conducted a real-world study to evaluate the effect of pyrrotinib on the OS of HER2+ breast cancer patients with brain metastases
.
The research results were published in the journal Clin Cancer Res
.

This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)
.
A total of 168 patients were included in the study.
Among them, 39 patients had brain metastases (BM) before pyrrotinib treatment, and 129 patients did not have BM
.
39 patients with brain metastases were divided into 17 patients with pyrrotinib combined with surgery or radiotherapy (S/R), and 22 patients without surgery or radiotherapy (NS/NR)
.

This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)
.
A total of 168 patients were included in the study.
Among them, 39 patients had brain metastases (BM) before pyrrotinib treatment, and 129 patients did not have BM
.
39 patients with brain metastases were divided into 17 patients with pyrrotinib combined with surgery or radiotherapy (S/R), and 22 patients without surgery or radiotherapy (NS/NR)
.
This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)
.
A total of 168 patients were included in the study.
Among them, 39 patients had brain metastases (BM) before pyrrotinib treatment, and 129 patients did not have BM
.
39 patients with brain metastases were divided into 17 patients with pyrrotinib combined with surgery or radiotherapy (S/R), and 22 patients without surgery or radiotherapy (NS/NR)
.
This study is a real-world study evaluating the OS, PFS, tumor mutation burden (TMB), clinical benefit rate (CBR) and objective response of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases (BM) Rate (ORR)
.
A total of 168 patients were included in the study.
Among them, 39 patients had brain metastases (BM) before pyrrotinib treatment, and 129 patients did not have BM
.
39 patients with brain metastases were divided into 17 patients with pyrrotinib combined with surgery or radiotherapy (S/R), and 22 patients without surgery or radiotherapy (NS/NR)
.

The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.

The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.
The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.
The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.
The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.
The study showed that Pyrotinib is an optional strategy for HER2+ breast cancer patients with brain metastases; its combined surgery or radiotherapy can improve the patient’s OS
.
Tumor mutational burden (TMB) may be a predictor of the efficacy of pyrrotinib treatment
.

For details, please refer to: Clin Cancer Res: The efficacy of Pyrotinib in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter study

For details refer to: Clin Cancer Res: Pyrotinib (Pyrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: A real-world multicenter study For details refer to: Clin Cancer Res: Pyrotinib (Pyrotinib) in the treatment of HER2+ breast cancer patientswith brain metastases Efficacy of cancer patients: real-world multi-center study.
Fordetails, please refer to:Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: Real-world multi-center study.
Fordetails: Fordetails: Fordetails: Fordetails: Fordetails Reference:Reference fordetails:Reference fordetails:Clin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ breast cancer patients with brain metastases: a real-world multicenter studyClin Cancer Res: Pyrotinib (pyrrotinib) in the treatment of HER2+ with brain Efficacy of patients with metastatic breast cancer: a real-world multicenter study

 

Leave a message here